Tardive dyskinesia in Chinese inpatients with chronic schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 27, Issue 6, 2003, Pages 1029-1036

  Leung, Siu Kau ^a   Ungvari, Gabor S ^b,c   Ng, Fung Shing ^a   Cheung, Hung Kin ^a   Leung, Tony ^b  

^a CASTLE PEAK HOSPITAL   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c SHATIN HOSPITAL   (Hong Kong)

Author keywords

Chinese; Prevalence; Schizophrenia; Tardive dyskinesia

Indexed keywords

ANTIPARKINSON AGENT; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CLOZAPINE; DISULFIRAM; HALOPERIDOL; LITHIUM; METOCLOPRAMIDE; NEUROLEPTIC AGENT; OLANZAPINE; PROCHLORPERAZINE; RISPERIDONE; TRIFLUOPERAZINE;

ADULT; AKATHISIA; ARTICLE; CATATONIA; CAUCASIAN; CHINESE; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DISEASE ASSOCIATION; DRUG INDUCED MOVEMENT DISORDER; DRUG USE; FEMALE; GENDER; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH SERVICE; MENTAL PATIENT; MOTOR DYSFUNCTION; NEGATIVE SYNDROME; OBSESSIVE COMPULSIVE DISORDER; ONSET AGE; PARKINSONISM; PREVALENCE; PSYCHOSIS; RANDOMIZATION; SCHIZOPHRENIA; SCORING SYSTEM; TARDIVE DYSKINESIA;

EID: 0141517139     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(03)00171-4     Document Type: Article

References (63)

1. American Psychiatric Association (APA) Diagnostic and Statistical Manual of Mental Disorders. 4th ed. 1994;American Psychiatric Association, Washington, DC.
2. Andreasen N.C. The Scale for Assessment of Negative Symptoms (SANS). 1983;University of Iowa Press, Iowa City, IO.
3. Baca-Garcia E., Stanilla J.K., Buchel C., Gattaz W.F., de Leon J. Diurnal variability of orofacial dyskinetic movements. Pharmacopsychiatry. 32:1999;73-75.
4. Barnes T.R.E. A rating scale for drug-induced akathisia. Br. J. Psychiatry. 154:1989;672-676.
5. Burnett G.B., Prange A.J., Wilson I.C., Joliff L.A., Creese J.C., Snyder S.H. Adverse effects of anticholinergic antiparkinsonian drugs in tardive dyskinesia. Neuropsychobiology. 6:1980;109-120.
6. Bush G., Fink M., Petrides G., Dowling F., Francis A. Catatonia. I. Rating scale and standardized examination. Acta Psychiatr. Scand. 93:1996;129-136.
7. Bush G., Petrides G., Francis A. Catatonia and other motor syndromes in a chronically hospitalized psychiatric population. Schizophr. Res. 27:1997;83-92.
8. Carroll B.T., Anfinson T.J., Kennedy J.C., Yendrek R., Boutros M., Bilon A. Catatonic disorder due to general medical conditions. J. Neuropsychiatry Clin. Neurosci. 6:1994;122-123.
9. Casey D.E. Spontaneous and tardive dyskinesias: clinical and laboratory studies. J. Clin. Psychiatry. 46:1985;42-47.
10. Casey D.E., Povlsen U.J., Meidahl B., Gerlach J. Neuroleptic-induced tardive dyskinesia and parkinsonism: changes during several years of continuing treatment. Psychopharmacol. Bull. 22:1986;250-253.
11. Chakos M.H., Alvir J.M.J., Woerner M.G., Koreen A., Geisler S., Mayerhoff D., Sobel S., Kane J.M., Borenstein M., Liebermann J. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch. Gen. Psychiatry. 53:1996;313-319.
12. Chaplin R., McGuigan S. Antipsychotic dose: from research to clinical practice. Psychiatr. Bull. 20:1996;452-454.
13. Chen C.N., Wong J., Lee N., Chan-Ho M.W., Lau J.T., Fung M. The Shatin community mental health survey: II. Major findings. Arch. Gen. Psychiatry. 50:1993;125-133.
14. Chen E.Y.H., Chen R.Y.L., Lam L., Nguyen D.G. Negative symptoms, neurological signs and neuropsychological impairments in 204 Hong Kong Chinese patients with schizophrenia. Br. J. Psychiatry. 168:1996;223-227.
15. Chiu H., Shum P., Lau J., Lam L.C.W. Prevalence of tardive dyskinesia, tardive dystonia, and respiratory dyskinesia among Chinese psychiatric patients in Hong Kong. Am. J. Psychiatry. 149:1992;1081-1085.
16. Chiu H., Lau J., Lam L., Shum P. Association of negative symptoms with tardive dyskinesia in schizophrenic patients. Aust. N. Z. J. Psychiatry. 27:1993;228-232.
17. Chong S.A. Tardive dyskinesia and CYP2D6 polymorphism in Chinese. Br. J. Psychiatry. 171:1997;586.
18. Chong S.A., Mahendran R., Machin D., Chua H.S., Parker G., Kane J. Tardive dyskinesia among Chinese and Malay patients with schizophrenia. J. Clin. Psychopharmacol. 22:2002;26-30.
19. Chouinard G., Annable L., Ross-Chouinard A., Nestoros J.N. Factors related to tardive dyskinesia. Am. J. Psychiatry. 136:1979;79-83.
20. Dixon L., Weiden P.J., Haas G., Sweeney J., Frances A.J. Increased tardive dyskinesia in alcohol-abusing schizophrenic patients. Compr. Psychiatry. 33:1992;1-12.
21. Endicott J., Spitzer R.L., Fleiss J.L., Cohen J. The global assessment scale. Arch. Gen. Psychiatry. 33:1976;766-771.
22. Garcia-Barcelo M.M., Lam L.C.W., Ungvari G.S., Lam V.K.L., Tang W.K. Dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients. J. Neural Transm. 108:2001;671-677.
23. Gardos G., Cole J.O. Drug-induced parkinsonism and concomitant tardive dyskinesia. Joseph A.B., Young R.R. Movement Disorders in Neurology and Neuropsychiatry. 1992;234-269 Blackwell Scientific, Cambridge, MA.
24. Gelenberg A.J. The catatonic syndrome. Lancet. 2:1976;1339-1341.
25. Gerlach J., Korsgaard S., Clemmesen P.et al. The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity. Acta. Psychiatr. Scand. 87:1993;244-252.
26. Goodman W.K., Price H., Rasmussen S.A., Mazure C., Flesichmann R.L., Hill C.L., Heninger G.R., Charney D.S. The Yale-Brown Obsessive Compulsive Scale: I. Development, use and reliability. Arch. Gen. Psychiatry. 46:1989;1006-1011.
27. Greil W., Haag H., Rossnagl G., Ruther E. Effect of anticholinergics on tardive dyskinesia: a controlled discontinuation study. Br. J. Psychiatry. 145:1984;304-310.
28. Guy W. NECDEU Assessment Manual for Psychopharmacology. 1976;76-338 U.S. DHEW Publication (ADM), ADAMHA, Rockville, MD.
29. Guy W., Ban T.A., Wilson W.H. An international survey of tardive dyskinesia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 9:1985;401-405.
30. Honigfeld G., Klett C.J. The Nurses' Observation Scale for Inpatient Evaluation (NOSIE) - a new scale for measuring improvement in chronic schizophrenia. J. Clin. Psychol. 21:1965;65-71.
31. Hosmer D.W., Lemeshow S. Applied Logistic Regression. 1989;Wiley, New York.
32. Jeste D.V., Caligiuri M.P. Tardive dyskinesia. Schizophr. Bull. 19:1993;303-315.
33. Jeste D.V., Karson C.K., Iager A.C., Bigelow L.B., Wyatt R.J. Association of abnormal involuntary movements and negative symptoms. Psychopharmacol. Bull. 20:1984;380-381.
34. Kane J.M. Drug therapy - schizophrenia. N. Engl. J. Med. 334:1996;34-71.
35. Kane J.M., Smith J.M. Tardive dyskinesia. Arch. Gen. Psychiatry. 39:1982;473-481.
36. Kane J.M., Woerner M., Borenstein M., Wegner J., Lieberman J.A. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull. 22:1982;254-258.
37. Kane J.M., Woerner M., Weinhold P., Wegner J., Kinon B. A prospective study of tardive dyskinesia development: preliminary results. J. Clin. Psychopharmacol. 2:1982;345-349.
38. Khot V., Wyatt R.J. Not all that moves is tardive dyskinesia. Am. J. Psychiatry. 148:1991;661-666.
39. Ko G.N., Zhang L.D., Yan W.W., Zhang M.D., Buchner D., Xia Z.Y., Wyatt R.J., Jeste D.V. The Shanghai 800: prevalence of tardive dyskinesia in a Chinese psychiatric hospital. Am. J. Psychiatry. 146:1989;387-389.
40. Kolakowska T., Williams A.O., Ardern M., Reveley M.A. Tardive dyskinesia under 60 years of age. Biol. Psychiat. 21:1986;161-169.
41. Koshino Y., Madokoro S., Ito T., Horie T., Mukai M., Isaki K. A survey of tardive dyskinesia in psychiatric inpatients in Japan. Clin. Neuropharmacol. 15:1992;34-43.
42. Lo T., Kwok I., Cheung T.K., Lau B., Cheung H.K. Tardive dyskinesia. J. Hong Kong Psychiatr. Assoc. 1:1981;18-25.
43. Lohr J.B., Wisniewski A.A. Movement Disorders: A Neuropsychiatric Approach. 1987;Guildford Press, New York.
44. McKenna P.J., Lund C.E., Mortimer A.M., Biggins C.A. Motor, volitional and behavioural disorders in schizophrenia 2: the "conflict of paradigms" hypothesis. Br. J. Psychiatry. 158:1991;328-336.
45. Morgenstern H., Glazer W.M. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Arch. Gen. Psychiatry. 50:1993;723-733.
46. Munetz M.R., Benjamin S. How to examine patients using the abnormal involuntary movement scale. Hosp. Commun. Psychiatry. 39:1988;1172-1177.
47. Muscettola G., Pampallona S., Barbato G., Castello M., Bollini P. Persistent tardive dyskinesia: demographic and pharmacologic risk factors. Acta. Psychiatr. Scand. 87:1993;29-36.
48. Effect of different neuroleptics in tardive dyskinesia and parkinsonism. Psychopharmacology. 90:1986;423-429.
49. Olivera A.A., Kiefer M.W., Manley N.K. Tardive dyskinesia in psychiatric patients with substance use disorders. Am. J. Drug Alcohol Abuse. 16:1990;57-66.
50. Owens D.G.C. Tardive dyskinesia. Owens G.G.C. A Guide to the Extrapyramidal Side-effects of Antipsychotic Drugs. 1999;166-226 Cambridge Univ. Press, Cambridge, UK.
51. Pi E.H., Gray G.E., Lee D.G., Ji Z., Weng Y., Kim C.K., Kim Y.S., Leung T.M., Kishimoto A., Wu C.L. Tardive dyskinesia in Asians: a multinational study. CME Syllabus and Scientific Proceedings in Summary Form, 143rd Annual Meeting of the American Psychiatric Association, Washington, DC. 1990;86 American Psychiatric Association, Washington, DC.
52. Pi E.H., Gutierrez M.A., Gray G.E. Tardive dyskinesia: cross-cultural perspectives. Lin K.M., Poland R.E., Nakasaki G. Psychopharmacology and Psychobiology of Ethnicity. 1993;153-167 American Psychiatric Press, Washington, DC.
53. Rogers D. The motor disorders of severe psychiatric illness: a conflict of paradigms. Br. J. Psychiatry. 147:1985;221-232.
54. Rosebush P.I., Hildebrand A.M., Furlong B.G.et al. Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation, and response to lorazepam. J. Clin. Psychiatry. 51:1990;357-362.
55. Schooler N.R., Kane J.M. Research diagnosis for tardive dyskinesia. Arch. Gen. Psychiatry. 39:1982;486-487.
56. Simpson G.M., Angus J.W.S. A rating scale for extrapyramidal side effects. Acta. Psychiatr. Scand. 45(Suppl. 212):1970;11-19.
57. Swartz J.R., Burgoyne K., Smith M., Gadasally R., Ananth J., Ananth K. Tardive dyskinesia and ethnicity: review of the literature. Ann. Clin. Psychiatry. 9:1997;53-59.
58. Tamminga C.A., Woerner M.G. Clinical course and cellular pathology of tardive dyskinesia. Davis K.L., Charney D., Coyle J.T., Nemeroff C. Neuropsychopharmacology. The Fifth Generation of Progress. 2002;1831-1841 Lippincott Williams & Wilkins, Philadelphia, PA.
59. Ungvari G.S., Chiu H.F.K., Lam L.C.W., Pang A.H.T., Chung D.S.W. Gradual withdrawal of long-term anticholinergic antiparkinson medication in chronic schizophrenia. J. Clin. Psychopharmacology. 19:1999;141-148.
60. Van Os J., Fahy T., Jones P., Harvey I., Toone B., Murray R. Tardive dyskinesia: who is at risk? Acta Psychiatr. Scand. 96:1997;206-216.
61. Williams J.B.W. A structured interview guide for the Hamilton Depression Rating Scale. Arch. Gen. Psychiatry. 45:1988;742-747.
62. Woerner M.G., Mannuzza S., Kane J.M. Anchoring the BPRS: an aid to improved reliability. Psychopharmacol. Bull. 24:1988;112-117.
63. Yassa R., Lal S., Korpassy A., Ally J. Nicotine exposure and tardive dyskinesia. Biol. Psychiatry. 22:1987;67-72.